Product Description
Mechanisms of Action: EP2 Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Ophthalmic
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AbbVie
Company Location: NORTH CHICAGO IL 60064
Company CEO: Richard A. Gonzalez
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Glaucoma, Open-Angle|Hypertension|Glaucoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
NCT01291108 | P2 |
Completed |
Hypertension|Glaucoma, Open-Angle |
2011-10-01 |
|
NCT01001195 | P2 |
Completed |
Hypertension|Glaucoma, Open-Angle |
2010-04-01 |
|
NCT00809848 | P2 |
Completed |
Glaucoma|Hypertension |
2009-05-01 |